But as an example, if we had partnered with a Big

Quote:

---

But as an example, if we had partnered with a Big Pharma (i.e. Merck, Eli Lily, Roche, etc....someone who would be a competitor to Gilead) last year March 2020 for COVID (excluding Long Haulers, as that wasn't known, and is really it's own unique pathology) we would have had the pull and the resources to have a larger trial and a more appropriate protocol, as we now have in Brazil. Subgroup data could have even pulled off an EUA if we had a true partner, especially if we had one of them running the trials, not us, so basically we just collect the paychecks when it's done.

---

I think you assume to much. First we would have had to have an offer. In March 2020 much less was known about Covid-19 and even less was known about how leronlimab could effect it. It's obvious outside of a small group of people that have studied leronlimab and the importance of CCR5 that it's possibilities are not appreciated. If BP had an inkling of what leronlimab could do they'd have bought out the company before March 2020.

Quote:

---

We could be worth a lot of money right now by taking only 30% of COVID, then we've got the rest of our indications to focus on.

---

Who's offering a deal based on a failed trial?